Since the approval of omalizumab in 2003, the development of biologic asthma, eczema and food allergy therapies have grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and more in development, the future of allergic biologic therapies is promising. Despite several well known complications or side effects, researchers remain focused on elucidating the complex pathophysiology of asthma, eczema and food allergy.
New and novel research is underway to develop the ground breaking truth of immune mechanisms for Th2 allergic inflammatory diseases (atopic asthma, atopic dermatitis, eosinophilic oesophagitis), drug allergy and food allergy.
The hope is that biologic therapies will eventually be tailored to an individual’s atopic phenotype. With more than 300 million people worldwide affected by an atopic condition and with roughly 5-10% of our population living with severe, uncontrolled asthma, eczema, hayfever or food allergy, the need for new biologic therapies remains high.
Anti-IgE therapies and biologic drugs block key steps in disease pathways to limit or prevent symptoms. Most therapeutic and biologic drugs are immune system proteins called antibodies. By binding to molecules that are active in disease, these antibody drugs can interfere with disease processes. Many biologic drugs approved for other uses are now being studied to treat asthma, food allergy, food allergy, either on their own or in combination with food-based immunotherapies. Our research and innovation, involves the latest cutting-edge studies to discover new asthma, eczema and food allergy treatments with national and international partners.